Susquehanna International Group, LLP Tg Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$17.21 - $25.28 $2.19 Million - $3.21 Million	127,100 Added 17.87%	838,400 $19.6 Million
Q2 2024 Aug 15, 2024	SELL	$13.32 - $19.19 $2.22 Million - $3.19 Million	-166,300 Reduced 18.95%	711,300 $12.7 Million
Q1 2024 May 07, 2024	SELL	$13.02 - $21.3 $4.21 Million - $6.89 Million	-323,400 Reduced 26.93%	877,600 $13.3 Million
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $1.2 Million - $3.39 Million	180,000 Added 17.63%	1,201,000 $20.5 Million
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $500,763 - $1.59 Million	59,900 Added 6.23%	1,021,000 $8.54 Million
Q2 2023 Aug 11, 2023	BUY	$15.48 - $35.0 $5.16 Million - $11.7 Million	333,200 Added 53.07%	961,100 $23.9 Million
Q1 2023 May 16, 2023	SELL	$10.23 - $19.34 $2.46 Million - $4.65 Million	-240,200 Reduced 27.67%	627,900 $9.44 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $2.28 Million - $5.38 Million	454,500 Added 109.89%	868,100 $10.3 Million
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $273,743 - $503,160	59,900 Added 16.94%	413,600 $2.45 Million

337

87.7M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.2B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.